Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Ruiz-Patinõ, AlejandroArrieta, OscarCardona-Mendoza, Andrés FelipeMartín, Claudio MarceloRaez, Luis EstuardoZatarain-Barrón, Zyanya LuciaBarron, FelicianoRicaurte, Luisa MaríaBravo-Garzón, María A.Mas, Luis A.Corrales, LuisRojas Puentes, LeonardoLupinacci, LorenaPerazzo, FlorenciaBas, Carlos ArturoCarranza, Omar E.Puparelli, CarmenRizzo, Miguel MRuiz, RossanaRolfo, ChristianArchila, PilarRodríguez, July F.Vargas Báez, Carlos AlbertoCarranza, HernánOtero, Jorge MiguelPino, Luis EduardoOrtíz, CarlosLaguado, PaolaRosell, Rafael Costa2020-03-092020-03-0920201759-7706https://hdl.handle.net/20.500.12495/2022application/pdfengAttribution 4.0 InternationalImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)articleEstadificación de neoplasiasSistema nervioso centralEstudios de cohortesAdultImmunotherapyLung neoplasmshttps://doi.org/10.1111/1759-7714.13272instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)Acceso abiertoinfo:eu-repo/semantics/openAccesshttps://purl.org/coar/access_right/c_abf3042020